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Abstract Seven head and neck oncology cooperative 
groups in the Netherlands have reviewed the epidemiol­
ogy, staging, treatment and survival of oropharyngeal
Presented at the combined meeting of the Society of Head 
and Neck Surgeons and the European Organization for Research 
and Treatment of Cancer, Paris, France, 25—28 May 1994
S. Mak-Kregar
Comprehensive Cancer Center, Amsterdam, The Netherlands 
F. J. M. Hilgers (El)
Department of Otolaryngology-Head and Neck Surgery,
The Netherlands Cancer Institute, Plesmanlaan 121,
NL-1066 CX Amsterdam, The Netherlands
F. J. M. Hilgers
Department of Otolaryngology, University Hospital,
Amsterdam, The Netherlands
P. C. Levendag
Department of Radiotherapy, Dr. Daniel Den Hoed Cancer Center, 
Rotterdam, The Netherlands
P. C. Levendag
Department of Otolaryngology, University Hospital,
Rotterdam, The Netherlands
J. J. Manni
Department of Otolaryngology, University Hospital,
Nijmegen, The Netherlands
H. Lubsen
Department of Otolaryngology, University Hospital,
Utrecht, The Netherlands
J. L. N. Roodenburg
Department of Maxillofacial Surgery, University Hospital, 
Groningen, The Netherlands
J. M. H. van der Beek
Department of Otolaryngology, University Hospital,
Maastricht, The Netherlands
J. M. H. van der Beek
Institute of Radiotherapy, Limburg, The Netherlands 
A. G. L. van der Meij
Department of Otolaryngology, University Hospital,
Leiden, The Netherlands
Present address:
1 Department of Otolaryngology, University Hospital,
Maastricht, The Netherlands
carcinoma patients treated between 1986 and 1990, In 
all, 640 patients with squamous cell carcinoma (628, 
98%) or undifferentiated carcinoma (12, 2%) referred for 
primary treatment were analyzed. The total group in­
cluded 441 males (69%) and 199 females (31%), with a 
median age of 59 years (range, 30-92). Tumor distribu­
tion by subsite was the tonsillar region (372 patients, 
58%), base of the tongue/vallecula (179, 28%), soft 
palate/uvula (62, 10%) and posterior oropharyngeal wall 
(27, 4%). Forty-four patients (7%) had stage I disease, 
106 (17%) had stage II disease, 157 (24%) stage III, and 
319 (50%) stage IV. Staging was unknown in 14 patients 
(2%). Radiotherapy was given to the primary tumor in 
408 patients (64%), surgery and radiotherapy to 147 
(23%), surgery alone to 42 (7%), other treatments to 14 
(2%) and no treatment to 29 patients (4%). The 5-year 
overall survival was 28% and the 5-year disease-specific 
survival was 41%. This latter survival was 35% in males 
and 51% in females ([P = 0.003). Five-year sui’vival by 
subsite was 54% in the soft palate/uvula, 42% in the ton­
sillar region, 33% in the base of the tongue and 32% in 
the posterior oropharyngeal wall (P  = 0.003). When ana­
lyzing survival by stage, 5 -year survival in patients with 
stage I disease was 68% and decreased significantly to 
27% in stage IV disease (P < 0.001). Best survival oc­
curred in patients treated with surgery alone (80%), was 
less in the group treated by surgery and radiotherapy 
(51%), and decreased further in patients treated by radio­
therapy alone (36%) (P<  0.0001). By multivariate analy­
sis, stage, sex and midline localization were found to be 
significant prognostic factors.
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Introduction
Oropharyngeal carcinoma is in general a low incidence 
tumor, accounting for 0.3-0.5%  of all malignancies [11, 
13] and predominantly affecting men in the sixth and sev­
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enth decades of life [3, 8, 20]. Since tumors usually are 
asymptomatic during their growth, most patients present 
with advanced tumors, i.e. stages III—IV of the 1987 
UICC system [22].
In the absence of convincing results from comparative 
studies optimal management is subject to an ongoing de­
bate. In general, patients with local or locoregional dis­
ease are offered treatment with a curative intent, being the 
case in approximately 80% of all patients [18]. The re­
mainder, suffering from disseminated disease and/or be­
ing in poor general condition, receive palliative treatment 
or no treatment at all. The main modalities of treatment 
with curative intent are surgery and radiotherapy, applied 
either as single modalities, often in stages I-II, or in com­
bination (stages III-IV),
When comparing results of treatment, 5-year overall 
survival rates of approximately 40% are regularly obtained 
without striking differences between treatment modali­
ties: [4, 7, 9-11, 23, 24]. However, occasional series have 
reported poorer (15—20%) [15] or better (62-64%) [1, 16] 
results. In these cases, the leading prognostic factor has 
been the extension of disease on admission [7, 17]. How­
ever, in predicting survival sex, age, general condition, 
tumor subsite, response to treatment and the presence or 
absence of second primary neoplasms also need to be con­
sidered, as they may significantly influence prognosis.
In order to answer questions about various factors af­
fecting malignancy, the Dutch Head and Neck Coopera­
tive Group has conducted a nationwide study in order to 
address issues of epidemiology, treatment and survival of 
patients with oropharyngeal carcinoma.
Materials and methods
Seven leading medical centers that participate in the Dutch Head 
and Neck Cooperative Group, i.e. the University Hospitals of 
Groningen, Leiden and Maastricht in combination with the Radio- 
therapeutic Institute of Limburg, Nijmegen and Rotterdam in co­
operation with the Dr. Daniel Den Hoed Cancer Center, Utrecht 
and The Netherlands Cancer Institute in combination with the Uni­
versity of Amsterdam, have participated in the present project. In 
the preparatory phase, feasibility and scope of the study, time 
schedule and practical aspects were examined using previous ex­
periences of the Cooperative Group [19]. Next, a checklist and re­
lated manual were designed for the purposes of the study. Each 
following step was taken upon reaching a consensus of the overall 
project design.
Data collection
In each participating center the charts of patients admitted between 
1986 and 1990 for treatment of oropharyngeal carcinoma were re­
viewed. Data related to epidemiology, staging, treatment and 
survival were collected using standardized checklists and re turend 
as hard copy to the Comprehensive Cancer Center, Amsterdam 
(IKA). There, a centralized data entry using a scientific informa­
tion retrieval (SIR) database, version 3.2, was performed. Patients 
who were admitted to more than one center were identified by 
cross-checking of epidemiological data, and totals were adjusted 
accordingly.
Patients
From 694 patient forms returned, 22 were excluded because of 
multiple admissions, 18 due to other tumor histologies and 8 for 
exceeding the study period. Additionally, 6 patients were receiving 
treatment for recurrent disease and were also excluded from the 
present review. Thus, 649 patients admitted for primary treatment 
of histologically proven squamous cell carcinoma (628 patients) or 
undifferentiated carcinoma (12 patients) of the oropharynx were 
analyzed. Among the total group, 441 patients (69%) were males 
and 199 (31%) females, with a median age of 59 years (range, 
30-92 years).
Patients were followed for at least 3 years, or until death, and 
were censored if they were lost to follow-up before the end of that 
period. Overall survival was defined as the time between the date 
of diagnosis and the end of follow-up or death, regardless of tumor 
status. In calculating disease-specific survival, only those patients 
who died with local, regional and/or distant disease from oropha­
ryngeal tumor were considered.
Statistical analysis
Survival curves were calculated using the life table method. Dis­
ease-specific survival was tested as a more appropriate indicator 
for mortality due to oropharyngeal carcinoma. Possible bias was 
examined by using Pearson’s chi-squared test to evaluate potential 
differences in assessment of tumor status at death at each partici­
pating center.
In the univariate analysis of disease-specific survival, the log 
rank test was applied. Single prognostic factors were tested in 
Cox's [2] proportional hazard model with stepwise backward elim­
ination,
Detailed analysis of locoregional recurrence rates in general 
and in the specific subsites will be published elsewhere. In this pa­
per analysis of all patients with respect to treatment and survival 
will be presented.
Results
Subsite localizations of tumor
Of the 640 oropharyngeal carcinomas, 372 (58%) origi­
nated from the tonsillar region, 179 (28%) from the base 
of the tongue, 62 (10%) from the soft palate/uvula and 27 
(4%) from the posterior oropharyngeal wall.
Five hundred and sixty-seven tumors (89%) originated 
from the lateral parts of the oropharynx, and 73 (11%) 
from the midline. Midline lesions encompassed 33 base 
of tongue tumors (18% of all tumors in this subsite), 11 
posterior wall lesions (41% of all), 27 soft palate/uvula 
neoplasms (43%) and 2 tonsillar region tumors that were 
grossly exceeding the midline. The prevalent side was 
left in 269 patients (42%) and right in 298 patients 
(47%).
Staging
UICC classifications and staging system from 1978 [21] 
and 1987 [22] were recorded. Distribution by tumor (T) 
was identical in both classifications and was as follows:
T l, 79 (12%); T2, 197 (31%); T3, 196 (31%); T4, 165 
(26%). The T stage was unknown in 3 patients. Using the 
1978 UICC classification, distribution by node (N) status
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was: NO, 258 (40%); N l, 235 (37%); N2, 72 (11%); N3, 
67 (11%). Nodal status was unknown in 8 patients (2%), 
When using the 1987 classification for N disease, 151 
cases were N l (24%)» 182 were N2 (28%) and 46 were 
N3 (7%). The vast majority of patients (620, 94%) was 
free of distant metastasis on admission, while 9 patients 
(1%) had métastasés and status for metastasis could not be 
determined in 29 patients (5%).
Distribution by stage using the 1978 UICC classifica­
tion was: 44 patients (7%) stage I; 106 patients (17%) 
stage II; 283 patients (44%) stage III; 188 patients (29%) 
stage IV; 19 patients (3%) with an unknown stage of the 
disease. With the 1987 UICC classification, 44 patients 
(7%) had stage I disease, 106 (17%) stage II disease, 157 
(24%) stage III disease and 319 (50%) stage IV disease
(Fig. 1).
Treatment
Of 640 patients, 500 (78%) were treated with intention to 
cure, 128 (20%) received palliative treatment and in the 
remaining 12 patients (2%) the intention of treatment was 
not clear in retrospect. The rate of patients who received 
palliation increased with the stage of the disease, and was 
2% in stage I and 34% in stage IV.
Treatment corresponded to standard protocols in each 
center in 530 patients (83%) and was deviant from the 
standard schedules in 98 (15%). Adherence to protocol 
was not clear in retrospect for 12 patients (2%). The rea­
sons to deviate from the standards were: poor general 
condition (26 patients, 4%), patient’s choice (20 patients, 
3%), second primary tumors (15 patients, 2%), participa­
tion in EORTC 22791 trial [6] (9 patients, 1%), disease 
progression during radiotherapy (6 patients, 1%), very ad­
vanced tumors (5 patients, 1%) and unknown site of pri­
mary tumor at the beginning of treatment (3 patients). In­
terestingly, high age was reported as the single reason for 
deviation from standard treatment in only 1 patient (83 
years of age).
Treatment modalities
Globally, treatment of the primary site consisted of radio­
therapy in 408 patients (64%), surgery and radiotherapy in 
147 patients (23%), surgery by wide local or composite 
resections in 42 patients (7%) and other fonns of treat­
ment (including chemotherapy) in 14 patients (2%). In to­
tal, neck node resections were performed in 217 patients 
(34%): radical (142 patients, 22%), modified (58 patients, 
9%) or selective (17 patients, 3%). Twenty-nine patients 
(4%) were not treated at all. Treatment modality by stage 
is shown in Fig. 2. A group of 63 patients who received 
radiotherapy to their primary tumors in combination with 
surgical treatment of the regional neck nodes were con­
sidered to be treated with radiotherapy alone for the pur­
pose of this report.
I
Vital status
All figures related to vital status and survival present 
“5-year” results (Table 1). Split up by center, some differ­
ences in tumor status at death were observed, but these are 
not likely to cause appreciable bias when disease-specific 
survival was analyzed rather than overall survival The ob­
served differences may well have been caused by chance
(P = 0.35).
Table 1 Vital status of 640 patients with oropharyngeal cancer 
CNED no evidence of disease)
Clinical status Patients
Alive, NED 225 (35%)
Alive, with tumor 17 (3%)
Dead, NED 74 (12%)
Dead, with tumor 316 (49%)
Lost to follow-up 8 ( 1%)
Total 640 (100%)
1 3 6
oropharyngeal carcinoma in the Netherlands 1986-1990 
percent disease specific survival
Table 2 A revised staging system for oropharyngeal cancer
time from diagnosis (months
Fig. 3 Disease-specific survival by stage (UICC 1987)
Survival
Overall survival was 28% and disease-specific survival 
was 41%. Overall survival in males was 22% and in fe­
males 39% (P = 0.0001), while disease-specific survival 
was 35% and 51% in males and females, respectively (P
-  0*003). Overall survival by subsite was 44% in the soft 
palate/uvula, 30% in the tonsillar region, 23% in the base 
of the tongue and 13% in the posterior oropharyngeal wall 
(P = 0.001). Corresponding figures for disease-specific 
survival in each site were 54%, 42%, 33% and 32%, re­
spectively (P = 0.003).
Overall survival per stage of disease (UICC, 1987) was 
50% in stage I and II, 28% in stage III and 16% in stage 
IV CP < 0.0001), As shown in Fig. 3, disease-specific sur­
vival for stage I disease was 68% and decreased signifi­
cantly to 27% for stage IV disease (P < 0.0001).
Disease-specific survival in patients treated by surgery 
was 80%, surgery and radiotherapy 51%, radiotherapy 
alone 36%, and treatment by other modalities 7% (P <
0.0001). Treatment including surgery (alone or in combi­
nation with radiotherapy) was associated with a higher 
disease-specific survival than radiotherapy alone: stage I, 
68% vs 34%; stage II, 81% vs 41%; stage III, 36% vs 
25%; stage IV, 31% vs 14% (P < 0.0001).
When split up by center, a difference in dis ease-spe­
cific survival was seen at 5 years, ranging from 24% to
64% CP = 0.009).
Univariate analysis
From analysis of disease-specific survival the following 
factors emerged as univariately statistically significant: 
sex CP = 0.003), age (P = 0.013), T status (P < 0.0001), N 
status (P < 0.0001), stage UICC 1987 (P < 0.0001), sub­
I T l-2 NO-1 M0
II T l-2 N2 M0
T3 N0-1 MO
T4 NO M0
III T l-2 N3 M0
T3 N2 M0
T4 Nl M0
IV T3 N3 M0
T4 N2-3 M0
Any T Any N Ml
Table 3 Multivariate analysis of disease-specific survival for oro-
pharyngeal cancer
Factor Pa Pb
Sex = 0.015 =0.006
Age =0.006 =0.084
Midline origin < 0.0001 < 0.0001
Revised stage < 0.0001 < 0.0001
Treatment modality <0.0051
Center = 0.21 = 0.23
a Controlled for all variables except for treatment modality 
b Controlled for all variables, including treatment modality
site involvement (P = 0.003), midline origin (P < 0.0001), 
treatment (P < 0.0001), and center (P = 0.009).
A revised staging system
In order to control for the prognostic factors obtained, the 
combination of T, N and M as proposed in the UICC stage 
grouping was tested. Parameters related to epidemiology, 
tumors and treatment available for 594 patients were en­
tered in the proportional hazard model. In this group of 
patients, regrouping of the existing T, N and M categories 
over the stages led to distribution superior to the UICC 
system. A detailed description of this staging system (see 
Table 2) will be published elsewhere [5].
Multivariate analysis
All prognostic factors obtained in the univariate analysis 
and the revised staging system were entered in a multi­
variate model. The prognostic role of the centers de­
creased when controlled for stage and midline origin (P =
0.051 and P  = 0.21 for the two staging systems, respec­
tively), leading to complete elimination of the prognostic 
value of the center when revised stage grouping was uti­
lized.
Stage, midline origin and sex appeared to have persis­
tent prognostic value throughout all analyses (P < 0.0001, 
P < 0.0001 and P  = 0.006, respectively).
Prognostic value of age was no longer significant after 
controlling for treatment (P = 0.084).
With respect to treatment, adherence to the standard 
protocols, surgery (plus radiotherapy) as compared to ra­
diotherapy and “other treatment” compared to no treat­
ment were associated with better disease-specific survival 
(P = 0.0019, 0.0051 and 0.015, respectively). P  values for 
the prognostic factors in the multivariate analysis are 
summarized in Table 3.
Discussion
In diseases with low incidence and no established treat­
ment recommendations, reviews of large numbers of 
patients provide valuable insights even when different 
treatment modalities and/or more clinical institutes are in­
volved. Short checklists with pragmatic questions about 
large numbers of patients are appropriate for obtaining 
sets of hard comparable data, and are feasible within a 
limited time span. The Dutch Head and Neck Cooperative 
Group has chosen this approach, realizing that some ques­
tions would remain unanswered but certain useful insights 
would be obtained. Earlier studies of the group have al­
ready clearly shown this [19].
The rate of missing values in our present study is re­
markably low. From 1989 to 1990, the Netherlands Can­
cer Registry reported findings in 447 patients with oro­
pharyngeal carcinoma, and found that T, N, M or subsite 
data were missing from 8-15% in cases reviewed (source; 
the Netherlands Cancer Registry), Our own findding of 
missing information in cases reviewed was less than 5%. 
Several reasons may be responsible for this discrepancy: 
quality of documentation over different hospitals, types of 
patients, motivation related to the study, etc. Specialized 
cancer centers participating in this study have more exten­
sive and often better structured documentation on cancer 
patients than do general hospitals. Secondly, patients not 
referred to cancer centers are more likely to be old or dis­
abled, have advanced disease and/or are not prepared to 
undergo rather extensive treatment. In such cases, an elab­
orate diagnostic work-up is often not performed and some 
data are invariably missing.
Our present study is estimated to have encompassed 
more than half of the patients with oropharyngeal carci­
noma managed in the Netherlands during the period stud­
ied. With respect to age, sex and histopathology, similar 
distributions were observed in this patient population and 
the one covered by the Cancer Registry, In the case of 
sub sites, T, N, M and stage of the disease, comparison is 
hampered by the discrepancies in missing values, but 
striking differences do not seem to emerge.
A significant influence of participating centers with re­
gard to survival in univariate analysis was initially ob­
served. However, when controlled for other significant 
prognostic factors (i.e. sex, differences in staging systems 
and midline origin of tumor), differences among centers 
decreased below the level of statistic significance. At­
tempts to compare one’s own results with other reports are 
not exceptional in the literature. Nevertheless, separate 
studies differ in methods of selecting, staging and treating
patients and/or in the extent of reporting on the various 
procedures employed. Even when a study methodology is 
standardized, striking differences may be found due to 
differences in patient populations and treatment. This ob­
servation emphasizes the urge for careful interpretation of 
data, particularly if they are obtained from separate inves­
tigators.
A comparison of treatment modalities with respect to 
end-results forms another pitfall. In our series superior 
survival rates were associated with surgery, with or with­
out radiotherapy, above radiotherapy alone. The differ­
ence was statistically significant even when controlled for 
other prognostic factors, including tumor stage. However, 
this outcome is not supported by other published papers. 
Again, false-positive conclusions regarding the prognostic 
significance of some factors or treatment modalities in 
particular may be drawn in the absence of careful analysis 
and interpretation of all data. The role of different treat­
ment modalities for oropharyngeal cancers managed in 
the Netherlands will be discussed in more detail in sub­
sequent papers, and in particular will deal with different 
subsites of the oropharynx.
One outcome of our present study is the evidence for a 
prognostic role of midline origin of oropharyngeal tu­
mors. Usually these tumors are split up by subsite, ton­
sillar carcinomas having better prognosis than base of 
tongue or posterior wall tumors [14]. However, the rela­
tionship between laterality of lesions and prognosis being 
more significant than the relation between anatomical 
subsite and prognosis had not been demonstrated before.
Despite the established prognostic role of disease stage, 
the optimal definition of stages is still subject to active 
research. The official committees of UICC and the Amer­
ican Joint Committee for Cancer Staging (AJCC) and in­
dependent authors regularly evaluate practical and prog­
nostic aspects of current staging systems. Proposals for 
improvement inevitably follow, as reflected by the UICC 
1987 and AJCC 1988 system [22], TANIS [12] and our 
revised system. The latter lead to a more balanced distrib­
ution of patients over stages and to a superior prognostic 
distinction when compared with earlier systems [5].
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